Press releases
- Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
- Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
- Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
- Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
More ▼
Key statistics
As of last trade Edwards Lifesciences Corp (EWLX:GER) traded at 81.24, -8.35% below its 52-week high of 88.64, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 81.24 |
---|---|
High | 81.24 |
Low | 81.24 |
Bid | 81.42 |
Offer | 81.60 |
Previous close | 80.72 |
Average volume | 362.89 |
---|---|
Shares outstanding | 602.60m |
Free float | 597.23m |
P/E (TTM) | 37.57 |
Market cap | 52.68bn USD |
EPS (TTM) | 2.33 USD |
Data delayed at least 15 minutes, as of May 10 2024 08:04 BST.
More ▼